GlassScriptPhysician profile
Catherine Luz
NPI 1578080651
$5,756.44
in general payments reported to CMS, 2019-2025
24 companies · $1,423 in 2025
The $1,423 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $837 · 2022: $1,230 · 2023: $1,009 · 2024: $1,257 · 2025: $1,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,181 · Education: $509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,181.02 |
| Education | $508.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,704.61 | 2021-2025 | |
| Amgen INC. | $571.30 | 2021-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $545.17 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $402.42 | 2021-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $401.96 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Pfizer INC. | $336.25 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $246.98 | 2022-2025 | |
| Genzyme Corporation | $241.73 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $229.74 | 2024-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $190.03 | 2021-2025 | Cabtreo, Jublia |
| Incyte Corporation | $171.32 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $148.47 | 2021-2024 | Adbry |
| Lilly USA, LLC | $134.62 | 2021-2024 | Taltz, Olumiant |
| Sanofi-Aventis U.S. LLC | $96.99 | 2025 | |
| Galderma Laboratories, L.P. | $73.85 | 2021-2025 | Aklief |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $60.63 | 2024 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $42.22 | 2024-2025 | Zoryve |
| Biofrontera INC. | $28.04 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Dermavant Sciences, INC. | $27.95 | 2023 | Vtama |
| Verrica Pharmaceuticals INC. | $24.95 | 2025 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.63 | 2025 | Spevigo |
| Epi Health, LLC | $23.67 | 2021 | |
| Organon LLC | $16.67 | 2025 | Vtama |
| Almirall LLC | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Luz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.